Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jinxin Fertility Group Limited
錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

VOLUNTARY ANNOUNCEMENT
PROPOSED ON-MARKET SHARE REPURCHASE

This announcement is made by Jinxin Fertility Group Limited (the "**Company**") on a voluntary basis.

Reference is made to the announcement of the Company dated June 26, 2025 in relation to, among others, the general mandate to repurchase (the "**Repurchase Mandate**") shares of the Company (the "**Shares**") granted by the shareholders of the Company at the annual general meeting of the Company held on June 26, 2025 (the "**AGM**"). Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 274,470,604 Shares, being 10% of the total issued Shares (excluding treasury Shares) as at the date of the AGM, on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Company believes that the current trading price of the Shares does not reflect their intrinsic value or the actual business prospects of the Company. As such, the board of directors (the "**Board**") of the Company has resolved to utilize the Repurchase Mandate to repurchase Shares in the open market from time to time at an aggregate price of not less than HK$100 million (the "**Proposed Share Repurchase**"). The Company believes that the Proposed Share Repurchase will demonstrate the Company's confidence in its own business outlook and prospects, and the current financial resources of the Company would enable it to implement the Proposed Share Repurchase, while maintaining a solid financial position.

The Company will conduct the Proposed Share Repurchase in strict compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on the Stock Exchange, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Act of the Cayman Islands and other applicable laws and regulations.

Shareholders and potential investors of the Company should note that any exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any Share

repurchases or whether or not the Company will make any repurchase at all. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang
Chief Executive Officer,
Acting Chief Financial Officer and
Executive Director

Hong Kong, December 1, 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. Dong Yang, Ms. Lyu Rong and Dr. Geng Lihong, as executive Directors; Mr. Zhong Yong, as Chairman and non-executive Director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive Directors; and Dr. Chong Yat Keung, Mr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.

* *For identification purposes only*